<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944784</url>
  </required_header>
  <id_info>
    <org_study_id>CY 5031</org_study_id>
    <secondary_id>2020-004040-29</secondary_id>
    <nct_id>NCT04944784</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>COURAGE-ALS</acronym>
  <official_title>A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional&#xD;
      outcomes in ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COURAGE-ALS is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv&#xD;
      in patients aged 18 to 80 with ALS.&#xD;
&#xD;
      The screening and qualification period for the trial will be no more than 14 days in&#xD;
      duration. Approximately 555 eligible ALS patients will be randomized (2:1) to receive the&#xD;
      following dose of reldesemtiv or placebo (stratified by riluzole use/non-use and edaravone&#xD;
      use/non-use) for the first 24 weeks (double-blind, placebo-controlled period):&#xD;
&#xD;
        -  300 mg reldesemtiv twice a day for a 600 mg total daily dose (TDD)&#xD;
&#xD;
        -  Placebo twice daily&#xD;
&#xD;
      At the end of the 24-week double-blind, placebo-controlled period, patients will transition&#xD;
      to the active drug period, where all patients will receive the following dose of reldesemtiv&#xD;
      for the next 24 weeks:&#xD;
&#xD;
        -  300 mg reldesemtiv twice a day for a 600 mg TDD for patients who were not down titrated&#xD;
           during the 24 weeks of blinded dosing&#xD;
&#xD;
        -  150 mg reldesemtiv twice a day for a 300 mg TDD for patients who were down titrated&#xD;
           during the 24 weeks of blinded dosing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of reldesemtiv versus placebo on functional outcomes in ALS</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 in ALS Functional Rating Scale-Revised (ALSFRS-R) total score; rating scale 0 to 48; higher scores indicate better functional status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of reldesemtiv versus placebo on combined functional and survival outcomes in ALS</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Combined assessment of change in ALSFRS-R total score, time to onset of respiratory insufficiency, and survival time up to Week 24. In this joint rank test each individual patient is ranked compared to all other patients based on survival time, time to onset of respiratory insufficiency, and changes from baseline to Week 24 in ALSFRS-R total score. Deaths have the worst rank (with earlier deaths being ranked worse than later deaths); patients with onset of respiratory insufficiency have the next worst rank; and the more favorable changes from baseline at week 24 in ALSFRS-R total score have the best rank using this process.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of reldesemtiv versus placebo on ventilatory function</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 in the percent predicted FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of reldesemtiv versus placebo on quality of life</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 in the ALS Assessment Questionnaire-40 (ALSAQ-40) total score; rating scale 0 to 100; higher scores indicate worse quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of reldesemtiv versus placebo on handgrip strength</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 in handgrip strength (average of both hands)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">555</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Day 1 until Week 24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Day 1 until Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo twice daily, from Day 1 until Week 24</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm take 2 placebo oral tablets twice a day from Day 1 until Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Week 24 until Week 48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48 for patients who were not down titrated during the 24 weeks of blinded dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg reldesemtiv twice daily for a 300 mg total daily dose, from Week 24 until Week 48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48 for patients who were down titrated for any reason during the 24 weeks of blinded dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reldesemtiv</intervention_name>
    <description>Reldesemtiv Oral Tablet</description>
    <arm_group_label>150 mg reldesemtiv twice daily for a 300 mg total daily dose, from Week 24 until Week 48</arm_group_label>
    <arm_group_label>300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Day 1 until Week 24</arm_group_label>
    <arm_group_label>300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Week 24 until Week 48</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Oral Tablet</description>
    <arm_group_label>Placebo twice daily, from Day 1 until Week 24</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or Females between the ages of 18 and 80 years of age, inclusive&#xD;
&#xD;
          -  Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported&#xD;
             probable, probable, or definite criteria for ALS according to the World Federation of&#xD;
             Neurology El Escorial criteria). Patients who meet the possible criteria are eligible&#xD;
             if they have lower motor neuron findings; those who have purely upper motor neuron&#xD;
             findings are ineligible.&#xD;
&#xD;
          -  First symptom of ALS ≤ 24 months prior to screening. The qualifying first symptoms of&#xD;
             ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory&#xD;
             muscles.&#xD;
&#xD;
          -  ALSFRS-R total score ≤ 44 at screening. Patients with a total score of 45 or higher&#xD;
             may be rescreened 60±7 days following the original screening date.&#xD;
&#xD;
          -  Upright FVC ≥ 65.0% of predicted for age, height, sex and ethnicity at screening&#xD;
             according to Global Lung Initiative equation&#xD;
&#xD;
          -  Must be either on riluzole for ≥ 30 days prior to screening or have not taken it for&#xD;
             at least 30 days prior to screening&#xD;
&#xD;
          -  Must have completed at least 2 cycles of edaravone at the time of screening or have&#xD;
             not received it for at least 30 days prior to screening&#xD;
&#xD;
          -  Able to swallow whole tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eGFRCysC &lt; 45.0 mL/min/1.73 m2 at screening&#xD;
&#xD;
          -  Urine protein/creatinine ratio &gt; 1 mg/mg (113 mg/mmol) at screening&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3-times the upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin (TBL), direct or indirect bilirubin above the ULN.&#xD;
&#xD;
          -  Cognitive impairment, related to ALS or otherwise that impairs the patient's ability&#xD;
             to understand and/or comply with study procedures and provide informed consent&#xD;
&#xD;
          -  Other medically significant neurological conditions that could interfere with the&#xD;
             assessment of ALS symptoms, signs or progression.&#xD;
&#xD;
          -  Has a tracheostomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cytokinetics, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytokinetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cytokinetics, MD</last_name>
    <phone>650-624-2929</phone>
    <email>medicalaffairs@cytokinetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center - Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shafeeq Ladha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine - ALS &amp; Neuromuscular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namita Goyal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - Forbes Norris MDA/ALS Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Katz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuen T. So, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Anschutz Outpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Quan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GW Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elham Bayat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pulley, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjorn E. Oskarsson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Carol and Frank Morsani Center for Advanced Health Care</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuan H. Vu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duchossois Center for Advanced Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kourosh Rezania</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey M. Statland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey D. Rothstein, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ximena Arcila-Londono, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Center for Advance Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TImothy M. Miller, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary L. Pattee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale J. Lange</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsy Andrews, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Bradshaw, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health Neuroscience Institute - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo McCluskey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kuenzler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daragh Heitzman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rup Tandan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VCU Neuroscience Orthopaedic and Wellness Center (NOW)</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Gwathmey, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Fee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Perron Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merrilee Needham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Korngut</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Johnston</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stan Cassidy Centre for Rehabilitation</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 0C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen O'Connell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Turnbull</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christen Shoesmith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Breiner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorne Zinman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Matte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University, Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Genge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Dionne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon City Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri Schellenberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>CK-2127107</keyword>
  <keyword>Reldesemtiv</keyword>
  <keyword>COURAGE-ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

